Filing Flows › Nexalin Technology (NXL) › Recalls, complaints & regulation
Nexalin Technology (NXL): clinical trials
Nexalin Technology (NXL) beyond its filings: 1 active clinical trial.
Nexalin Technology's latest quarter
Nexalin Technology, Q2 2026: revenue $12K (-83% year over year), net loss $2.2M, operating cash flow −$1.8M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Nexalin Technology have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.